High HER2 Intratumoral Heterogeneity Is a Predictive Factor for Poor Prognosis in Early-Stage and Locally Advanced HER2-Positive Breast Cancer.
Tomonori TaneiShigeto SenoYoshiaki SotaTakaaki HatanoYuri KitaharaKaori AbeNanae MasunagaMasami TsukabeTetsuhiro YoshinamiTomohiro MiyakeMasafumi ShimodaHideo MatsudaKenzo ShimazuPublished in: Cancers (2024)
High HER2 heterogeneity is a poor prognostic factor in patients with HER2-positive breast cancer. A novel approach to heterogeneity, which is manifested by the shape of HER2 FISH distributions, might be clinically useful in the prognosis prediction of patients after HER2 adjuvant therapy.
Keyphrases
- positive breast cancer
- prognostic factors
- poor prognosis
- early stage
- single cell
- long non coding rna
- locally advanced
- end stage renal disease
- squamous cell carcinoma
- ejection fraction
- rectal cancer
- neoadjuvant chemotherapy
- peritoneal dialysis
- radiation therapy
- clinical trial
- sentinel lymph node
- phase ii study
- open label